The effect of anti-angiogenic therapy and antibody therapy for distant metastasis in osteosarcoma.
| Project/Area Number |
22591672
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Aichi Cancer Center Research Institute |
|---|
Principal Investigator |
SUGIURA Hideshi 愛知県がんセンター(研究所), 腫瘍免疫学部, 研究員 (50303615)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KYOGASHIMA Mamoru 日本薬科大学, 薬学部, 教授 (50225091)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 骨 / 軟部腫瘍 / 抗IL-2α抗体 / 抗IL-2抗体 / 制御性T細胞 / FACS / LM8 / 骨肉腫 / 肺転移 / マウス / 肝転移 / Foxp3 / 抗IL2レセプタα単抗体 / 抗IL2単抗体 / 抑制性T細胞 |
|---|
| Research Abstract |
We evaluated the antitumor activity of anti-interleukin 2 receptor (IL2R) α(CD25) monoclonal antibody (PC61) or an anti-interleukin-2 monoclonal antibody (S4B6) in a murine osteosarcoma model (LM8). Tumors size and the numbers of lung and liver metastatic colonies were significantly decreased in both PC61 and S4B6 groups. Flow cytometry revealed that mouse regulatory T cells (Treg) can be deleted by intraperitoneal injection of PC61 or S4B6. Next, we examined the effectiveness of PC61 or S4B6 combined with Candesartan, but there were significantly no differences. It was suggested that PC61 and S4B6 strongly will suppress metastases and tumor progression.
|
Report
(4 results)
Research Products
(10 results)
